Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Lung Cancer. 2017 Mar 29;108:173–182. doi: 10.1016/j.lungcan.2017.03.017

Figure 3. Survival analysis of patients with stage III non-small-cell lung cancer treated with concurrent-alone or concurrent-consolidation chemoradiation by regimen and sequence.

Figure 3

a) OS and b) CSS did not vary by chemotherapy regimen for patients treated with chemoradiation. Concurrent-consolidation resulted in improved outcomes compared to concurrent-alone, with c) a median OS of 21 months versus 18 months, and d) a median CSS of 23 months versus 19 months. Median follow up was 29 months, and curves are truncated at 36 months. Data is not shown where n < 11 to protect patient identity.